Case Number 112024 - Preventing the Induction of Fatty Acid Oxidation in Response to S6K1 Inactivation
Contact: Michael Hansen
Description: Dr. David Plas and his lab have identified a new method that
enhances cancer cell cytotoxicity when used in
combination with Rapamycin.
Although Rapamycin suppresses glycolysis in cancer
cells, the cytotoxic benefit of Rapamycin is
unexpectedly low in many cancers. Agents that inhibit
fatty acid oxidation in tumor cells can compensate for
this shortcoming by blocking a key metabolic pathway
that cancer cells use to survive during Rapamycin
A provisional patent is pending.
You can learn more in this article: S6K1 determines the metabolic requirements for BCR-ABL survival and this summary: Preventing the Induction of Fatty Acid Oxidation in Response to S6K1 Inactivation